Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ocugen Inc (NQ: OCGN ) 1.020 +0.030 (+3.03%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,618,073 Open 0.9900 Bid (Size) 1.010 (16) Ask (Size) 1.020 (56) Prev. Close 0.9900 Today's Range 0.9900 - 1.050 52wk Range 0.3450 - 2.105 Shares Outstanding 257,328,085 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference September 24, 2024 From Ocugen Via GlobeNewswire Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire Performance YTD +55.11% +55.11% 1 Month -23.31% -23.31% 3 Month -28.67% -28.67% 6 Month -37.80% -37.80% 1 Year +150.80% +150.80% More News Read More Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop September 09, 2024 From Ocugen Via GlobeNewswire Peering Into Ocugen's Recent Short Interest August 09, 2024 Via Benzinga Why Ocugen (OCGN) Stock Is Falling August 01, 2024 Via Benzinga Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit September 05, 2024 From Ocugen Via GlobeNewswire Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Ocugen Via GlobeNewswire Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy August 28, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication August 26, 2024 From Ocugen Via GlobeNewswire Ocugen (OCGN) Q2 2024 Earnings Call Transcript August 08, 2024 Via The Motley Fool Topics Earnings Exposures Financial Ocugen Provides Business Update with Second Quarter 2024 Financial Results August 08, 2024 From Ocugen Via GlobeNewswire InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering August 06, 2024 Via Investor Brand Network Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa August 05, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock August 02, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock July 31, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Proposed Public Offering of Common Stock July 31, 2024 From Ocugen Via GlobeNewswire Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results July 29, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy July 25, 2024 From Ocugen Via GlobeNewswire 1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid July 11, 2024 Via The Motley Fool 3 Penny Stocks That Could Turn $10K Into $100K in 3 Years July 06, 2024 Via InvestorPlace 7 A-Rated Penny Stocks to Beat June Gloom June 24, 2024 Via InvestorPlace Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease June 21, 2024 From Ocugen Via GlobeNewswire 3 Penny Stocks Set to Make New Millionaires in 2024 June 20, 2024 Via InvestorPlace Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication June 20, 2024 From Ocugen Via GlobeNewswire Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
